Company
Supernus Pharms
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
5
4 still marketed
Novel approvals
1
Approvals since 2021
3
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Qelbree new use Apr 29, 2022
- Qelbree approved NovelApr 2, 2021
- Gocovri new use OrphanFeb 1, 2021
- Oxtellar Xr new use Dec 13, 2018
- Osmolex Er approved Feb 16, 2018
- Gocovri approved OrphanAug 24, 2017
- Trokendi Xr new use Apr 5, 2017
- Trokendi Xr new use Apr 5, 2017
- Trokendi Xr new use Aug 18, 2016
- Trokendi Xr approved Aug 16, 2013
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (4)
Newest FDA action first.
- Trokendi Xr Topiramate · 2013
- Gocovri Amantadine Hydrochloride · 2017
- Qelbree Viloxazine Hydrochloride · 2021
- Oxtellar Xr Oxcarbazepine · 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.